The objective of this study is to describe the evolution of hypodopaminergic syndrome in patients with Parkinson's disease.
All patients to be included have been clinically described in the early phase of their disease, before instauration of dopaminergic treatment, in the context of a former study ("Non Motor Aspects in De Novo Parkinson's Disease (Honeymoon) NCT02786667") between june 2012 and june 2016. 3 to 5 years after this study, those patients who started dopaminergic treatment will be evaluated again. The objective of this study, which takes place 3 to 5 year after the initial evaluation, is to measure the evolution of apathy and other symptoms of the hypodopaminergic syndrome. Secondary objectives are the evolution of other parameters including pain, personality and behavior. All parameters measured have been determined of each patient in the Honeymoon study.
Study Type
OBSERVATIONAL
Enrollment
90
The degree of apathy will be evaluated with the "Starkstein scale of Apathy"
University Hospital of Grenoble
Grenoble, France
Hôpital Neurologique Pierre Wertheimer
Lyon, France
Centre Expert Régional pour la maladie de Parkinson
Poitiers, France
Hôpital de Hautepierre
Strasbourg, France
Evolution of apathy in Parkinson's disease
Evolution of apathy in Patients with Parkinson's disease under dopaminergic treatment. The degree of apathy is evaluated with the "Starkstein Scale of Apathy".
Time frame: 1day
Evolution of hypodopaminergia in Parkinson's disease
Evolution of hypodopaminergic symptoms in Patients with Parkinson's disease under dopaminergic treatment. Hypodopaminergic symptoms are evaluated with different scales: ECMP (behavioral evaluation in Parkinsons's disease) for depression and anxiety, STAI (State-trait-anxiety inventory, self-assessment-questionnaire for anxiety, BDI (Beck depression inventory) for depression, PFS-16 (Piper Fatigue Sale) for fatigue. Hypodopaminergia is the expressed as the sum of its symptoms.
Time frame: 1 day
Apparition of hyperdopaminergic symptoms in Parkinson's disease
Apparition of hyperdopaminergic symptoms in patients with Parkinson's disease under dopaminergic treatment, with the questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP) and the ECMP scale.
Time frame: 1 day
Evolution of impulsivity in Parkinson's disease
Evolution of impulsivity in patients with Parkinson's disease under dopaminergic treatment. Evaluation with a self-assessment-questionnaire (UPPS Impulsive Behavior Scale)
Time frame: 1 day
Evolution of personality in Parkinson's disease
Evolution of personality in patients with Parkinson's disease under dopaminergic treatment with the self-assesment-questionnaire "Temperament and Character Inventory" (TCI).
Time frame: 1 day
Evolution of pain in Parkinson's disease
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Evolution of pain in patients with Parkinson's disease under dopaminergic treatment with the self-assessment-questionnaire NPSI (Neuropathic Pain Symptom Inventory).
Time frame: 1 day
Evolution of quality of life in Parkinson's disease
Evolution of quality of life in patients with Parkinson's disease under dopaminergic treatment with the self-assessment-questionnaire PDQ39 (Parkinson's disease questionnaire).
Time frame: 1 day
Evolution of somnolence in Parkinson's disease
Evolution of somnolence in patients with Parkinson's disease under dopaminergic treatment with the ECMP scale.
Time frame: 1 day
Evolution of eating behavior in Parkinson's disease
Evolution of eating behavior in patients with Parkinson's disease under dopaminergic treatment with the self-assesment-questionnaire "Dutch Eating Behavior Questionnaire" - DEBQ.
Time frame: 1 day